AbbVie Near $10.9 Billion Deal to Acquire Apogee Therapeutics
AbbVie is reportedly close to acquiring clinical-stage biotech company Apogee Therapeutics in a cash deal valued at $10.9 billion, representing a 60% premium over its recent market cap of about $6.8 billion. The acquisition marks AbbVie's largest since 2019 and highlights the pharmaceutical giant’s interest in early-stage drug candidates.
Topics: Biotech Acquisition Corporate Strategy Pharmaceuticals